1
|
Di Martino O, Niu H, Hadwiger G, Kuusanmaki H, Ferris MA, Vu A, Beales J, Wagner C, Menéndez-Gutiérrez MP, Ricote M, Heckman C, Welch JS. Endogenous and combination retinoids are active in myelomonocytic leukemias. Haematologica 2021; 106:1008-1021. [PMID: 33241677 PMCID: PMC8017822 DOI: 10.3324/haematol.2020.264432] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2020] [Indexed: 12/17/2022] Open
Abstract
Retinoid therapy transformed response and survival outcomes in acute promyelocytic leukemia (APL) but has demonstrated only modest activity in non-APL forms of acute myeloid leukemia (AML). The presence of natural retinoids in vivo could influence the efficacy of pharmacologic agonists and antagonists. We found that natural RXRA ligands, but not RARA ligands, were present in murine MLL-AF9-derived myelomonocytic leukemias in vivo and that the concurrent presence of receptors and ligands acted as tumor suppressors. Pharmacologic retinoid responses could be optimized by concurrent targeting of RXR ligands (e.g., bexarotene) and RARA ligands (e.g., all-trans retinoic acid), which induced either leukemic maturation or apoptosis depending on cell culture conditions. Co-repressor release from the RARA:RXRA heterodimer occurred with RARA activation, but not RXRA activation, providing an explanation for the combination synergy. Combination synergy could be replicated in additional, but not all, AML cell lines and primary samples, and was associated with improved survival in vivo, although tolerability of bexarotene administration in mice remained an issue. These data provide insight into the basal presence of natural retinoids in leukemias in vivo and a potential strategy for clinical retinoid combination regimens in leukemias beyond APL.
Collapse
Affiliation(s)
- Orsola Di Martino
- Department of Internal Medicine, Washington University, St Louis, Missouri, 63110
| | - Haixia Niu
- Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 3333
| | - Gayla Hadwiger
- Department of Internal Medicine, Washington University, St Louis, Missouri, 63110
| | - Heikki Kuusanmaki
- Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki, 00014
| | - Margaret A Ferris
- Department of Pediatrics, Washington University, St Louis, Missouri, 63110
| | - Anh Vu
- Department of Internal Medicine, Washington University, St Louis, Missouri, 63110
| | - Jeremy Beales
- Department of Internal Medicine, Washington University, St Louis, Missouri, 63110
| | - Carl Wagner
- School of Mathematical and Natural Sciences, Arizona State University, Phoenix, Arizona, 85281 USA
| | - María P Menéndez-Gutiérrez
- Myocardial Pathophysiology Area, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, 28029
| | - Mercedes Ricote
- Myocardial Pathophysiology Area, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, 28029
| | - Caroline Heckman
- Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki, 00014
| | - John S Welch
- Department of Internal Medicine, Washington University, St Louis, Missouri, 63110
| |
Collapse
|
2
|
Chiang ACA, Seua AV, Singhmar P, Arroyo LD, Mahalingam R, Hu J, Kavelaars A, Heijnen CJ. Bexarotene normalizes chemotherapy-induced myelin decompaction and reverses cognitive and sensorimotor deficits in mice. Acta Neuropathol Commun 2020; 8:193. [PMID: 33183353 PMCID: PMC7661216 DOI: 10.1186/s40478-020-01061-x] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2020] [Accepted: 10/17/2020] [Indexed: 12/20/2022] Open
Abstract
Frequently reported neurotoxic sequelae of cancer treatment include cognitive deficits and sensorimotor abnormalities that have long-lasting negative effects on the quality of life of an increasing number of cancer survivors. The underlying mechanisms are not fully understood and there is no effective treatment. We show here that cisplatin treatment of mice not only caused cognitive dysfunction but also impaired sensorimotor function. These functional deficits are associated with reduced myelin density and complexity in the cingulate and sensorimotor cortex. At the ultrastructural level, myelin abnormalities were characterized by decompaction. We used this model to examine the effect of bexarotene, an agonist of the RXR-family of nuclear receptors. Administration of only five daily doses of bexarotene after completion of cisplatin treatment was sufficient to normalize myelin density and fiber coherency and to restore myelin compaction in cingulate and sensorimotor cortex. Functionally, bexarotene normalized performance of cisplatin-treated mice in tests for cognitive and sensorimotor function. RNAseq analysis identified the TR/RXR pathway as one of the top canonical pathways activated by administration of bexarotene to cisplatin-treated mice. Bexarotene also activated neuregulin and netrin pathways that are implicated in myelin formation/maintenance, synaptic function and axonal guidance. In conclusion, short term treatment with bexarotene is sufficient to reverse the adverse effects of cisplatin on white matter structure, cognitive function, and sensorimotor performance. These encouraging findings warrant further studies into potential clinical translation and the underlying mechanisms of bexarotene for chemobrain.
Collapse
|
3
|
Ai X, Mao F, Shen S, Shentu Y, Wang J, Lu S. Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPARγ/PTEN/mTOR signaling pathway. BMC Cancer 2018; 18:407. [PMID: 29642873 PMCID: PMC5896077 DOI: 10.1186/s12885-018-4224-x] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2015] [Accepted: 03/13/2018] [Indexed: 12/11/2022] Open
Abstract
Background Thirty to 40 % of non-small cell lung cancer (NSCLC) patients developed higher hypertriglyceridemia in the process of treatment with bexarotene. And bioinformatics studies discovered that the expression of slc10a2 was increased in high-grade hypertriglyceridemia patients. So, we will explore the mechanism which may involve in this process. Methods We constructed slc10a2 overexpressed A549 cells and H1299 cells as cell models, normal A549 cells and H1299 cells as control. Then we explored the effects of slc10a2 on A549 cells and H1299 cells behaviors, including proliferation, invasion and apoptosis. The expression of apoptotic related genes and anti-cancer genes also been detected. Results We found that the proliferation and migration were inhibited and the apoptosis of NSCLC cells was accelerated by bexarotene. In addition, overexpressed slc10a2 in NSCLC cells can further suppress the proliferation and migration, and promote apoptosis under the treatment of bexarotene. On the contrary, the opposite results were obtained after slc10a2 gene was silenced in NSCLC cells treated with bexarotene. Moreover, the expression of caspase 3, caspase 7, PTEN, P21, P53, LKB1, TSC2 were increased and the expression of Bcl-2, cyclin D1, c-FLIP were declined in NSCLC cells and slc10a2 overexpressed NSCLC cells with the treatment of bexarotene, and the opposite situations were seen after slc10a2 gene was silenced in NSCLC cells. The further studies revealed the increased expression of slc10a2 activated the expression of peroxisome proliferator-activated receptor γ (PPARγ), then up-regulated PTEN expression and down-regulated mTOR expression. Conclusion These results suggest that bexarotene inhibits the viability of lung cancer cells via slc10a2/PPARγ/PTEN/mTOR signaling pathway. Electronic supplementary material The online version of this article (10.1186/s12885-018-4224-x) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Xinghao Ai
- Department of Medical Oncology, Changzheng Hospital, The Second Military Medical University, Shanghai, 200433, China.,Lung Tumor Clinical Medical Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, 200030, China
| | - Feng Mao
- Lung Tumor Clinical Medical Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, 200030, China
| | - Shengping Shen
- Lung Tumor Clinical Medical Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, 200030, China
| | - Yang Shentu
- Lung Tumor Clinical Medical Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, 200030, China
| | - Jiejun Wang
- Department of Medical Oncology, Changzheng Hospital, The Second Military Medical University, Shanghai, 200433, China.
| | - Shun Lu
- Lung Tumor Clinical Medical Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, 200030, China.
| |
Collapse
|
4
|
Wang Y, Rong J, Zhang J, Liu Y, Meng X, Guo H, Liu H, Chen L. Morphology, in vivo distribution and antitumor activity of bexarotene nanocrystals in lung cancer. Drug Dev Ind Pharm 2016; 43:132-141. [PMID: 27588517 DOI: 10.1080/03639045.2016.1225752] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
The objective of this study was to develop and evaluate the morphology, biodistribution and antitumor activity of bexarotene nanocrystals delivery system. The morphology was investigated using scanning electron microscopy (SEM), transmission electron microscopy (TEM), atomic force microscope and bexarotene nanocrystals exhibited the advantages of making the efficacy more steady and durable compared with control group in lung with less cardiac accumulation as shown by biodistribution studies in vivo. In addition, MTT assay, flow cytometry analysis, observation of morphological changes and apoptotic body demonstrated that bexarotene nanocrystals could significantly enhance the in vitro cytotoxicity and induced G1 cycle arrest and apoptosis against A549 cells. Also, bexarotene nanocrystals had significant antitumor activity in mice bearing A549 cell line. This finding was correlated with both in vitro and in vivo. Thereby, the overall results suggest that the bexarotene nanocrystals represent a potential source of medicine, which made bexarotene nanocrystals a promising candidate for the treatment of lung cancer.
Collapse
Affiliation(s)
- Yongjie Wang
- b Department of Pharmaceutics , School of Pharmaceutical Sciences, Shandong University , Jinan , 250012 , P.R. China
| | - Jinghong Rong
- a Department of Pharmaceutics , School of Pharmaceutical Sciences, Liaoning University , Shenyang , 110036 , P.R. China
| | - Jiaozhen Zhang
- c Department of Natural Products Chemistry, Key Lab of Chemical Biology (MOE) , School of Pharmaceutical Sciences, Shandong University , Jinan , 250012 , P.R. China
| | - Yu Liu
- a Department of Pharmaceutics , School of Pharmaceutical Sciences, Liaoning University , Shenyang , 110036 , P.R. China
| | - Xuelian Meng
- a Department of Pharmaceutics , School of Pharmaceutical Sciences, Liaoning University , Shenyang , 110036 , P.R. China
| | - Hejian Guo
- b Department of Pharmaceutics , School of Pharmaceutical Sciences, Shandong University , Jinan , 250012 , P.R. China
| | - Hongsheng Liu
- d Research Center for Computer Simulating and Information Processing of Bio-macromolecules of Liaoning Province , Shenyang , 110036 , P.R. China
| | - Lijiang Chen
- a Department of Pharmaceutics , School of Pharmaceutical Sciences, Liaoning University , Shenyang , 110036 , P.R. China.,d Research Center for Computer Simulating and Information Processing of Bio-macromolecules of Liaoning Province , Shenyang , 110036 , P.R. China
| |
Collapse
|
5
|
Wang Y, Liu X, Zhang J, Liu G, Liu Y, Wang K, Yang M, Cheng H, Zhao Z. Structural characterization and in vitro antitumor activity of polysaccharides from Zizyphus jujuba cv. Muzao. RSC Adv 2015. [DOI: 10.1039/c4ra13350a] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Complete structural characterization and in vitro antitumor activity of polysaccharides from Zizyphus jujuba cv. Muzao.
Collapse
Affiliation(s)
- Yongjie Wang
- School of Pharmaceutical Sciences and Center for Pharmaceutical Research & Drug Delivery Systems
- Shandong University
- Jinan 250012
- China
| | - Xinquan Liu
- School of Pharmaceutical Sciences and Center for Pharmaceutical Research & Drug Delivery Systems
- Shandong University
- Jinan 250012
- China
| | - Jiaozhen Zhang
- Department of Natural Products Chemistry
- Key Lab of Chemical Biology (MOE)
- School of Pharmaceutical Sciences
- Shandong University
- Jinan 250012
| | - Guangpu Liu
- School of Pharmaceutical Sciences and Center for Pharmaceutical Research & Drug Delivery Systems
- Shandong University
- Jinan 250012
- China
| | - Yan Liu
- School of Pharmaceutical Sciences and Center for Pharmaceutical Research & Drug Delivery Systems
- Shandong University
- Jinan 250012
- China
| | - Kaiming Wang
- School of Pharmaceutical Sciences and Center for Pharmaceutical Research & Drug Delivery Systems
- Shandong University
- Jinan 250012
- China
| | - Min Yang
- School of Pharmaceutical Sciences and Center for Pharmaceutical Research & Drug Delivery Systems
- Shandong University
- Jinan 250012
- China
| | - Huiling Cheng
- Medical Research Center
- Shandong Provisional Qianfoshan Hospital
- Jinan 250014
- China
| | - Zhongxi Zhao
- School of Pharmaceutical Sciences and Center for Pharmaceutical Research & Drug Delivery Systems
- Shandong University
- Jinan 250012
- China
| |
Collapse
|
6
|
Li L, Liu Y, Wang J, Chen L, Zhang W, Yan X. Preparation, in vitro and in vivo evaluation of bexarotene nanocrystals with surface modification by folate-chitosan conjugates. Drug Deliv 2014; 23:79-87. [DOI: 10.3109/10717544.2014.904455] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Affiliation(s)
- Li Li
- School of Pharmaceutical Sciences, Liaoning University, Shengyang, Liaoning Province, China
| | - Yu Liu
- School of Pharmaceutical Sciences, Liaoning University, Shengyang, Liaoning Province, China
| | - Jinjing Wang
- School of Pharmaceutical Sciences, Liaoning University, Shengyang, Liaoning Province, China
| | - Lijiang Chen
- School of Pharmaceutical Sciences, Liaoning University, Shengyang, Liaoning Province, China
| | - Wenjun Zhang
- School of Pharmaceutical Sciences, Liaoning University, Shengyang, Liaoning Province, China
| | - Xichen Yan
- School of Pharmaceutical Sciences, Liaoning University, Shengyang, Liaoning Province, China
| |
Collapse
|
7
|
Affiliation(s)
- Pengxiang Huang
- Metabolic Signaling and Disease Program, Sanford-Burnham Medical Research Institute, Orlando, FL 32827, USA
| | - Vikas Chandra
- Metabolic Signaling and Disease Program, Sanford-Burnham Medical Research Institute, Orlando, FL 32827, USA
| | - Fraydoon Rastinejad
- Metabolic Signaling and Disease Program, Sanford-Burnham Medical Research Institute, Orlando, FL 32827, USA
| |
Collapse
|
8
|
Chen L, Wang Y, Zhang J, Hao L, Guo H, Lou H, Zhang D. Bexarotene nanocrystal-Oral and parenteral formulation development, characterization and pharmacokinetic evaluation. Eur J Pharm Biopharm 2013; 87:160-9. [PMID: 24333772 DOI: 10.1016/j.ejpb.2013.12.005] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2013] [Revised: 11/28/2013] [Accepted: 12/08/2013] [Indexed: 12/26/2022]
Abstract
Bexarotene (Targretin®) is a synthetic retinoid that selectively activates the retinoid X receptor subfamily of retinoid receptors and exhibits potent anti-tumor activity. However, the poor solubility and bioavailability limit its application. The main aim of this study is to investigate the potential of oral and parenteral nanocrystals in enhancing the bioavailability of bexarotene. In this work, the orthogonal design was used to screen the optimum stabilizers and precipitation-combined microfluidization method was employed to obtain the optimal nanocrystals. According to DSC, X-ray diffraction analysis and Raman examination, the nanocrystals were still in crystalline state after the preparation procedure. By reducing the particle size, the in vitro dissolution rate of bexarotene was increased significantly. The in vivo test was carried out in rats and pharmacokinetic parameters of the bexarotene solution and bexarotene nanocrystals were compared after gavage and intravenous administration. The higher AUC and lower Cmax indicated that oral bexarotene nanocrystals significantly increased the bioavailability of bexarotene and decreased its side effects. Compared to the oral nanocrystals, the intravenous nanocrystals cut losses and increased bioavailability because of the absence of first pass effect and enterohepatic circulation.
Collapse
Affiliation(s)
- Lijiang Chen
- Department of Natural Products Chemistry, Key Lab of Chemical Biology (MOE), School of Pharmaceutical Sciences, Shandong University, Jinan, PR China; Department of Pharmaceutics, School of Pharmaceutical Sciences, Liaoning University, Shenyang, PR China
| | - Yongjie Wang
- Department of Pharmaceutics, School of Pharmaceutical Sciences, Liaoning University, Shenyang, PR China
| | - Jiaozhen Zhang
- Department of Natural Products Chemistry, Key Lab of Chemical Biology (MOE), School of Pharmaceutical Sciences, Shandong University, Jinan, PR China
| | - Leilei Hao
- Department of Pharmaceutics, School of Pharmaceutical Sciences, Shandong University, Jinan, PR China
| | - Hejian Guo
- Department of Pharmaceutics, School of Pharmaceutical Sciences, Shandong University, Jinan, PR China
| | - Hongxiang Lou
- Department of Natural Products Chemistry, Key Lab of Chemical Biology (MOE), School of Pharmaceutical Sciences, Shandong University, Jinan, PR China.
| | - Dianrui Zhang
- Department of Pharmaceutics, School of Pharmaceutical Sciences, Shandong University, Jinan, PR China.
| |
Collapse
|